A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension

Pediatr Nephrol. 2007 May;22(5):695-701. doi: 10.1007/s00467-006-0399-5. Epub 2007 Jan 10.


The pharmacokinetic (PK) parameters of lisinopril were obtained in 46 children aged 6 months to 15 years. A lisinopril suspension (0.15 mg/kg per day) was administered to patients <6 years of age; the remaining children received lisinopril tablets, the daily dose being adjusted according to body weight, i.e., 2.5 mg if <25 kg, 5 mg if 25-45 kg, and 10 mg if >45 kg. Blood was drawn predose and on eight occasions postdose in children aged 4-15 years, and on five occasions in those aged <4 years. PK data are reported for the 46 children in terms of age groups: Group I (n=9), aged 6-23 months; Group II (n=8), aged 2-5 years; Group III (n=12), aged 6-11 years; Group IV (n=17), aged 12-15 years. The dose of lisinopril ranged from 3.07 mg/m(2) per day in Group I to 4.78 mg/m(2) per day in Group IV. C(max) of lisinopril, which occurred 5-6 h postdose, varied from 22 ng/ml in Groups I and II to 44 ng/ml in Groups III and IV; AUC(0-24 h) ranged from 301-311 ng.h/ml in Groups I and II to 550-570 ng.h/ml in Groups III and IV. No serious adverse events related to lisinopril were reported.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Antihypertensive Agents / blood
  • Antihypertensive Agents / pharmacokinetics
  • Antihypertensive Agents / therapeutic use
  • Blood Specimen Collection
  • Child
  • Child, Preschool
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Hypertension / drug therapy*
  • Infant
  • Lisinopril / blood
  • Lisinopril / pharmacokinetics*
  • Lisinopril / therapeutic use
  • Male
  • Metabolic Clearance Rate


  • Antihypertensive Agents
  • Lisinopril